Ginkgo Bioworks Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Ginkgo Bioworks Holdings has a total shareholder equity of $1.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.7B and $568.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$944.07m |
| Equity | US$1.10b |
| Total liabilities | US$568.19m |
| Total assets | US$1.67b |
Recent financial health updates
No updates
Recent updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28Ginkgo Bioworks: May The Ginkgo King Grow
Sep 13Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?
Aug 26Gingko Bioworks: Near-Term Challenges Trump Downstream Economics
Aug 17Ginkgo Bioworks: Time To Buy
Aug 10Financial Position Analysis
Short Term Liabilities: DNA's short term assets ($1.0B) exceed its short term liabilities ($163.9M).
Long Term Liabilities: DNA's short term assets ($1.0B) exceed its long term liabilities ($404.3M).
Debt to Equity History and Analysis
Debt Level: DNA is debt free.
Reducing Debt: DNA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DNA has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 25% each year.